123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease

Movement Disorders

Volumn 13, Issue 3, 1998, Pages 438-445

  Wenning, Gregor K ^a,b   Donnemiller, Eveline ^a   Granata, Roberta ^a   Riccabona, Georg ^a   Poewe, Werner ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

CIT; Dopamine receptors; IBZM; Parkinson's disease; SPECT imaging

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; IODINE 123; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; BENZAMIDE DERIVATIVE; CARRIER PROTEIN; COCAINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BRAIN ASYMMETRY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CEREBELLUM; CORPUS STRIATUM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING;

AGED; BENZAMIDES; CARRIER PROTEINS; CEREBELLUM; COCAINE; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031595572     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130311     Document Type: Article

References (36)

1. Poewe W, Wenning GK. The natural history of Parkinson's disease. Neurology 1996;47:146-152.
2. Brücke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka J. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 1993;94:137-146.
3. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci 1993;90:11965-11969.
4. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
5. Laihinen AO, Rinne JO, Nagren KA, et al. PET studies on brain monoamine transporters with Carbon-11-β-CIT in Parkinson's disease. J Nucl Med 1995;36:1263-1267.
6. Kaufman MJ, Madras B. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-49.
7. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
8. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinson's disease. Ann Neurol 1994; 36:759-764.
9. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
10. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119:585-591.
11. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatrie disorders. J Cereb Blood Flow Metab 1991;11:220-228.
12. Brücke T, Wenger S, Asenbaum S, et al. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neural 1993;6:494-500.
13. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with parkinsonism. Neurology 1992;42:556-561.
14. Knable MB, Jones DW, Coppola R, et al. Lateralized differences in Iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 1995;36:1216-1225.
15. Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59.
16. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease - a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
18. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiviness in parkinsonian syndromes. Lancet 1990;7:336.
19. Neumeyer JL, Wang S, Milius RA, et al. [123-I]-2-β-Carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991;34:3144-3146.
20. De Paulis T, Kumar Y, Johansson L, et al. Potential neuroleptic agents. Chemistry and antidopaminergic properties of substituted 6-metnoxysalicidamides. J Med Chem 1985;28:1263-1269.
21. Verhoeff NP, Sokole EB, Stabin M, et al. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med 1993;20: 747-752.
22. Kuikka JT, Bergstrom KA, Ahonen A, Lansimies E. The dosimetry of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane. Eur J Nucl Med 1994;21:53-56.
23. Pan X, Wong WH, Chen CT, Liu J. Correction for photon attenuation in SPECT: analytical framework, average attenuation factors, and a new hybrid approach. Phys Med Biol 1993;38:1219-1234.
24. Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I]beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
25. Kung HF, Alavi A, Chang W, et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990;31:573-579.
26. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21:97-103.
27. 123I β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm 1997;50(suppl):9-24.
28. Lee CS, Schulzer M, Mak E, Hammerstad JP, Calne S, Calne DB. Patterns of asymmetry do not change over the course of idiopathic parkinsonism. Neurology 1995;45:435-439.
29. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
30. Verhoeff NPLG. Pharmacological implications for neuroreceptor imaging. Eur J Nucl Med 1991:482-502.
31. Perlmutter JS, Kilbourn MR, Raichle ME, Welch MJ. MPTP-induced up-regulation of in vivo dopaminergic radioligand-binding in humans. Neurology 1987;37:1575-1579.
32. 11C]raclopride. Mov Disord 1997;12:33-38.
33. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978;273:59-61.
34. Leenders KL, Aquilonius SM, Bergström K, et al. Unilateral MPTP lesion in the rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 1988;445:61-67.
35. Guttman M, Seeman P. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's disease striatum. J Neural Transm 1985;64:93-103.
36. Rinne JO, Laihinen A, Rinne UK, Nagren K, Bergman J, Ruotsalainen. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993;8:134-138.